Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03477006 · ClinicalTrials.gov registry record · Phase 3
Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial
A Phase 3 study, sponsored by Jason Sperry.
- Terminated
- Registry status
- Phase 3
- Development phase
- 86
- Enrollment target
NCT03477006: Clinical Trial Phase 3 study, sponsored by Jason Sperry.
NCT03477006 is a Phase 3 study that was terminated before completion, run by Jason Sperry. The registered enrollment target is 86 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03477006, a Phase 3 study, was terminated before completion, sponsored by Jason Sperry.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 86 participants
- Enrollment target
Study Summary
Despite advances in trauma resuscitation, a paucity of therapeutic interventions are available early enough to reduce the downstream morbidity and mortality attributable to hemorrhage, shock and coagulopathy. Due to the time sensitive nature of the treatment of hemorrhage, the ideal resuscitation intervention would entail use of a blood product containing all essential hemostatic components, closest to time of injury, where prevention or reversal of the devastating downstream consequences of shock and coagulopathy can occur. This proposal will characterized the efficacy of whole blood resuscitation initiated in the prehospital setting to patients in hemorrhagic shock which represents this ideal intervention post-injury. These results will have great potential to dramatically change the way trauma resuscitation occurs today.
Primary Outcome
28 day all cause mortality
Interventions
- BIOLOGICAL Whole blood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2018-11-20 |
| Est. Completion | 2020-10-30 |
| Phase | Phase 3 |
Why NCT03477006 stopped before completion
NCT03477006 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Whole blood is the first listed.
NCT03477006 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03477006 about?
NCT03477006 is a clinical study titled "Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial". Despite advances in trauma resuscitation, a paucity of therapeutic interventions are available early enough to reduce the downstream morbidity and mortality attributable to hemorrhage, shock and coagulopathy. Due to the time sensitive nature of the treatment of hemorrhage, the ideal resuscitation in...
What is the current status of trial NCT03477006?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 86 participants. The study started on 2018-11-20. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT03477006?
The interventions under investigation include: Whole blood (BIOLOGICAL).
Who is sponsoring clinical trial NCT03477006?
This trial is sponsored by Jason Sperry, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03477006's enrollment target sits among peer trials
86 1745th of 2000 higher than 254 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI